- Home
- AIRI vs IMNN Comparison
AIRI vs IMNN Comparison
Compare AIRI & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRI
- IMNN
- Stock Information
- Founded
- AIRI 1979
- IMNN 1982
- Country
- AIRI United States
- IMNN United States
- Employees
- AIRI N/A
- IMNN N/A
- Industry
- AIRI Military/Government/Technical
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- AIRI Industrials
- IMNN Health Care
- Exchange
- AIRI Nasdaq
- IMNN Nasdaq
- Market Cap
- AIRI 13.4M
- IMNN 12.1M
- IPO Year
- AIRI N/A
- IMNN 1985
- Fundamental
- Price
- AIRI $3.29
- IMNN $0.71
- Analyst Decision
- AIRI
- IMNN Buy
- Analyst Count
- AIRI 0
- IMNN 2
- Target Price
- AIRI N/A
- IMNN $14.00
- AVG Volume (30 Days)
- AIRI 45.6K
- IMNN 1.9M
- Earning Date
- AIRI 08-13-2025
- IMNN 08-13-2025
- Dividend Yield
- AIRI N/A
- IMNN N/A
- EPS Growth
- AIRI N/A
- IMNN N/A
- EPS
- AIRI N/A
- IMNN N/A
- Revenue
- AIRI $53,182,000.00
- IMNN N/A
- Revenue This Year
- AIRI $5.59
- IMNN N/A
- Revenue Next Year
- AIRI $5.00
- IMNN N/A
- P/E Ratio
- AIRI N/A
- IMNN N/A
- Revenue Growth
- AIRI 0.29
- IMNN N/A
- 52 Week Low
- AIRI $3.00
- IMNN $0.37
- 52 Week High
- AIRI $9.44
- IMNN $3.65
- Technical
- Relative Strength Index (RSI)
- AIRI 41.01
- IMNN 38.66
- Support Level
- AIRI $3.33
- IMNN $0.70
- Resistance Level
- AIRI $3.39
- IMNN $0.86
- Average True Range (ATR)
- AIRI 0.14
- IMNN 0.08
- MACD
- AIRI -0.01
- IMNN -0.03
- Stochastic Oscillator
- AIRI 6.25
- IMNN 3.03
About AIRI Air Industries Group
Air Industries Group is an aerospace and defense company. Its manufactures and designs structural parts and assemblies that focus on flight safety, including landing gear, arresting gear, engine mounts, flight controls, throttle quadrants, jet engines, and other components. The company also provides sheet metal fabrication of aerostructures, tube bending, and welding services.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).